PMID- 32826941
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20210821
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Aug 21
TI  - Proton pump inhibitor use and risk of hip fracture in patients with type 2 
      diabetes.
PG  - 14081
LID - 10.1038/s41598-020-70712-9 [doi]
LID - 14081
AB  - Type 2 diabetes mellitus (T2DM) is associated with a high rate of comorbidity, 
      including osteoporosis and peptic ulcers. Proton pump inhibitors (PPIs) are a 
      group of acid-suppressing drugs commonly used for treating peptic ulcers. 
      However, observational studies have reported an association between PPI therapy 
      and osteoporotic fractures. This study investigated the association between PPI 
      use and hip fracture (HFx) among patients with T2DM. We conducted this 
      population-based propensity-matched retrospective cohort study using the National 
      Health Insurance Research Database in Taiwan. Patients newly diagnosed with T2DM 
      between 2000 and 2008 were identified. After excluding those who previously used 
      PPIs or suffered HFx, 398,885 patients were recruited (44,341 PPI users; 354,544 
      non-users). HFx risk data from 2000 to 2013 were collected to calculate the 
      cumulative rate of HFx in these two groups. Sensitivity analyses were conducted 
      to evaluate the effects of PPI dose. After propensity score matching of 1:4, 
      44,431 and 177,364 patients were assigned to the PPI user and non-user groups, 
      respectively. PPI user group showed an increased risk of HFx with an adjusted 
      hazard ratio of 1.41 (95% CI 1.29-1.54) without dose-response relationship. Thus, 
      there is an increased risk of HFx in patients with T2DM receiving long-term PPI 
      treatment.
FAU - Chou, Ya-Shuan
AU  - Chou YS
AD  - Orthopaedic Research Center, College of Medicine, Kaohsiung Medical University 
      Hospital, Kaohsiung Medical University, No.100, Tzyou 1st Road, Kaohsiung, 807, 
      Taiwan.
AD  - Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical 
      University, Kaohsiung, Taiwan.
FAU - Jiang, He-Jiun
AU  - Jiang HJ
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, E-Da 
      Hospital, Kaohsiung, Taiwan.
FAU - Chen, Chung-Hwan
AU  - Chen CH
AD  - Orthopaedic Research Center, College of Medicine, Kaohsiung Medical University 
      Hospital, Kaohsiung Medical University, No.100, Tzyou 1st Road, Kaohsiung, 807, 
      Taiwan.
AD  - Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical 
      University, Kaohsiung, Taiwan.
AD  - Department of Orthopedics, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 
      Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
AD  - Department of Orthopaedics, College of Medicine, Kaohsiung Medical University 
      Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
FAU - Ho, Pei-Shan
AU  - Ho PS
AD  - Faculty of Dental Hygiene, College of Dental Medicine, Kaohsiung Medical 
      University, Kaohsiung, Taiwan.
FAU - Lee, Tien-Ching
AU  - Lee TC
AUID- ORCID: 0000-0002-1510-8079
AD  - Orthopaedic Research Center, College of Medicine, Kaohsiung Medical University 
      Hospital, Kaohsiung Medical University, No.100, Tzyou 1st Road, Kaohsiung, 807, 
      Taiwan. tn916943@gmail.com.
AD  - Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical 
      University, Kaohsiung, Taiwan. tn916943@gmail.com.
AD  - Department of Orthopedics, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 
      Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. 
      tn916943@gmail.com.
AD  - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University 
      Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. tn916943@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200821
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Female
MH  - Hip Fractures/chemically induced/epidemiology/*etiology
MH  - Humans
MH  - Insurance, Health
MH  - Male
MH  - Middle Aged
MH  - Osteoporosis/*complications
MH  - Osteoporotic Fractures/chemically induced/epidemiology/etiology
MH  - Peptic Ulcer/complications/*drug therapy
MH  - Propensity Score
MH  - Proportional Hazards Models
MH  - Proton Pump Inhibitors/*adverse effects/therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
PMC - PMC7443131
COIS- The authors declare no competing interests.
EDAT- 2020/08/23 06:00
MHDA- 2020/12/18 06:00
PMCR- 2020/08/21
CRDT- 2020/08/23 06:00
PHST- 2020/05/21 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
PHST- 2020/08/21 00:00 [pmc-release]
AID - 10.1038/s41598-020-70712-9 [pii]
AID - 70712 [pii]
AID - 10.1038/s41598-020-70712-9 [doi]
PST - epublish
SO  - Sci Rep. 2020 Aug 21;10(1):14081. doi: 10.1038/s41598-020-70712-9.